Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Press

Showing results (201-210 of 272) with videos related to

Pageof 28
Sort By:
Bone Marrow Transplantation|October 9, 2007
The impact of histologic grade on the outcome of high-dose therapy and autologous stem cell transplantation for follicular lymphomaR N Pham, T A Gooley, G E Keeney, et al.
Blood|November 15, 2014
Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313Daniel O Persky, Thomas P Miller, Joseph M Unger, et al.
Bone Marrow Transplantation|May 24, 2016
Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myelomaD J Green, W I Bensinger, L A Holmberg, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 18, 2016
Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for LymphomaSolomon A Graf, Jennifer E Vaughn, Thomas R Chauncey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2001
Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomasM S Kaminski, A D Zelenetz, O W Press, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 4, 2011
Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantationRon Ram, Ted A Gooley, David G Maloney, et al.
Blood|March 28, 2015
A roadmap for discovery and translation in lymphomaDavid M Weinstock, Riccardo Dalla-Favera, Randy D Gascoyne, et al.
Leukemia & Lymphoma|June 29, 2010
Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology ConsortiumAjay K Gopal, Oliver W Press, Andrei R Shustov, et al.
British Journal of Haematology|January 6, 2017
Results of a phase I-II study of fenretinide and rituximab for patients with indolent B-cell lymphoma and mantle cell lymphomaAndrew J Cowan, Phillip A Stevenson, Ted A Gooley, et al.
Blood|June 12, 2009
Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primatesDamian J Green, John M Pagel, Eneida R Nemecek, et al.
Pageof 28

Showing results (201-210 of 272) with videos related to

Sort By:
Pageof 28
Bone Marrow Transplantation|October 9, 2007
The impact of histologic grade on the outcome of high-dose therapy and autologous stem cell transplantation for follicular lymphomaR N Pham, T A Gooley, G E Keeney, et al.
Blood|November 15, 2014
Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313Daniel O Persky, Thomas P Miller, Joseph M Unger, et al.
Bone Marrow Transplantation|May 24, 2016
Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myelomaD J Green, W I Bensinger, L A Holmberg, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 18, 2016
Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for LymphomaSolomon A Graf, Jennifer E Vaughn, Thomas R Chauncey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2001
Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomasM S Kaminski, A D Zelenetz, O W Press, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 4, 2011
Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantationRon Ram, Ted A Gooley, David G Maloney, et al.
Blood|March 28, 2015
A roadmap for discovery and translation in lymphomaDavid M Weinstock, Riccardo Dalla-Favera, Randy D Gascoyne, et al.
Leukemia & Lymphoma|June 29, 2010
Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology ConsortiumAjay K Gopal, Oliver W Press, Andrei R Shustov, et al.
British Journal of Haematology|January 6, 2017
Results of a phase I-II study of fenretinide and rituximab for patients with indolent B-cell lymphoma and mantle cell lymphomaAndrew J Cowan, Phillip A Stevenson, Ted A Gooley, et al.
Blood|June 12, 2009
Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primatesDamian J Green, John M Pagel, Eneida R Nemecek, et al.
Pageof 28